MyRisk: Efficacy and Safety Evaluation of Oral Akynzeo® in Patients Receiving MEC At High Risk of Developing CINV Based on a Prediction Tool: a Multinational and Multicenter Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Netupitant/palonosetron (Primary) ; Dexamethasone; Dexamethasone; Dolasetron; Granisetron; Granisetron; Ondansetron; Ondansetron; Palonosetron; Palonosetron; Tropisetron; Tropisetron
Indications Chemotherapy-induced nausea and vomiting
Focus Therapeutic Use
Acronyms MyRisk
Sponsors Helsinn Healthcare SA

04 Dec 2024 Status changed from active, no longer recruiting to completed.
31 Aug 2024 This trial has been completed in Czechia according to European Clinical Trials Database record.
17 Apr 2024 Planned End Date changed from 30 Nov 2024 to 31 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com